Daclatasvir dihydrochloride (DCLD) is useful for treatment of hepatitis caused by Hepatitis C virus. The present work is aimed at development of polybutylcyanoacrylate microcapsules and to evaluate at In-vitro level including pharmacokinetic parameters using albino rats. PBCA microcapsules of DCLD were prepared by emulsion polymerization method. Eight formulations like F1 and F8 were tried. Six formulations such as F3 to F8 were obtained in discrete microcapsule form. Their particle size ranged in 126.3 to 499.7 µm was satisfactory. Percent drug content values in the range of 96.5% ±0.89 to 99.7%±0.56. Ex-vivo permeation studies revealed 99.3% of drug diffusion from formulation F5 after 24 hrs indicating fair GI absorption. Drug diffusion from pure drug was also reasonable with 51.9 %. But pharmacokinetic parameters are further estimated for formulation F5 to assess elimination half life of F5 compared to pure drug as this study will give an idea about prolonged therapeutic effect of the drug against HCV virus. There is enhancement of t1/2 (3.68 hr), AUC0-12(3960ng.hr/ml), and Ka (0.98hr-1) of PBCA microcapsules compared to pure drug indicating enhanced bioavailability of drug which will give way for prolonged exposure of virus present in blood to the drug to treat hepatitis C virus.